Cargando…

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs

Cycling of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients due to non-response is a problem preventing and delaying disease control. We aimed to assess and validate treatment response of b/tsDMARDs among clusters of RA patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalweit, Maria, Burden, Andrea M., Boedecker, Joschka, Hügle, Thomas, Burkard, Theresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266686/ https://www.ncbi.nlm.nih.gov/pubmed/37267387 http://dx.doi.org/10.1371/journal.pcbi.1011073

Ejemplares similares

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis
por: Lechtenboehmer, C. A., et al.
Publicado: (2021)

Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network
por: Kalweit, Maria, et al.
Publicado: (2021)

Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland
por: Burkard, Theresa, et al.
Publicado: (2022)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab
por: Burkard, Theresa, et al.
Publicado: (2023)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis
por: Holdsworth, Elizabeth A., et al.
Publicado: (2021)

Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry
por: Lin, Ching-Tsai, et al.
Publicado: (2021)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
por: Cappelli, Laura C., et al.
Publicado: (2023)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
por: Jung, Ju-Yang, et al.
Publicado: (2023)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
por: Rigby, William F. C., et al.
Publicado: (2017)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
por: Cho, Soo-Kyung, et al.
Publicado: (2017)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
por: Zago, Basiru Ahmad, et al.
Publicado: (2020)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
por: Karadeniz, Hazan, et al.
Publicado: (2022)

Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland
por: Vallejo-Yagüe, Enriqueta, et al.
Publicado: (2021)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
por: Lukas, Cédric, et al.
Publicado: (2019)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Biological or targeted synthetic DMARDs increase COVID-19 severity
Publicado: (2021)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Applied machine learning and artificial intelligence in rheumatology
por: Hügle, Maria, et al.
Publicado: (2020)

Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
por: Richter, A, et al.
Publicado: (2016)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment
por: Miwa, Yusuke, et al.
Publicado: (2017)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_vv121j3egujoc8kridsth0mqd7